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Abstract: The transcription factor NF-κB is a critical regulator of immune and inflammatory 
responses. In mammals, the NF-κB/Rel family comprises five members: p50, p52, p65 (Rel-
A), c-Rel, and Rel-B proteins, which form homo- or heterodimers and remain as an inactive 
complex with the inhibitory molecules called IκB proteins in resting cells. Two distinct NF-κB 
signaling pathways have been described: 1) the canonical pathway primarily activated by 
pathogens and inflammatory mediators, and 2) the noncanonical pathway mostly activated by 
developmental cues. The most abundant form of NF-κB activated by pathologic stimuli via the 
canonical pathway is the p65:p50 heterodimer. Disproportionate increase in activated p65 and 
subsequent transactivation of effector molecules is integral to the pathogenesis of many chronic 
diseases such as the rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and 
even neurodegenerative pathologies. Hence, the NF-κB p65 signaling pathway has been a piv-
otal point for intense drug discovery and development. This review begins with an overview of 
p65-mediated signaling followed by discussion of strategies that directly target NF-κB p65 in 
the context of chronic inflammation.
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Introduction
The NF-κB signaling system is a highly dynamic protein interaction network made 
up of components that regulate each other. The system includes five transcriptional 
monomers, two precursor proteins, three ankyrin repeat containing inhibitory IκB 
proteins, three stimulus-responsive inhibitory kinases (IKK complex: IKK-α and 
IKK-β, and IKK-γ or NF-κB essential modulator/NEMO), and ankyrin repeat con-
taining regulatory proteins.1 While all NF-κΒ translational monomers that function 
as homo- or heterodimers share conserved amino terminal dimerizing rel homology 
domain (RHD), only RelA/p65, C-rel, and RelB possess the transactivation domain 
(TAD) necessary for transcriptional activity. The TAD lacking monomers p50 or p52 
function as trans-repressors as homodimers but can stimulate transcription when 
heterodimerized with a transactivating Rel subunit.2
In resting state, the NF-κB dimers remain in the cytoplasm as an inactive complex 
with the IκΒ inhibitory proteins that mask the nuclear localization signals (NLSs) in the 
RHD and block their nuclear import.2,3 Activation of NF-κB occurs through canonical 
or noncanonical pathways and depends on phosphorylation-induced ubiquitination of 
IκB proteins. The canonical NF-κB pathway is activated within minutes of exposure to 
proinflammatory signals such as cytokines, pathogens, and danger-associated molecular 
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patterns. It is mediated by activation of the NEMO-containing 
IKK complex, which in turn designates the classical IκBs 
(IκBα, IκBβ, or IκBε) for degradation with consequent 
release of the NF-κB dimers for nuclear translocation.2–4 The 
noncanonical NF-κB pathway is triggered by developmental 
cues that signal via a select group of receptors such as a sub-
set of tumor necrosis factor family of receptors (TNFRs), B 
cell-activating factor receptor, lymphotoxin β receptor, and 
receptor activator of NF-κB and occurs at slower kinetics.5,6 
It is mediated by NF-κB inhibitory kinase (NIK) independent 
of NEMO. The NIK in turn phosphorylates and activates 
IKKα, which in turn directly acts on the non-IκB substrates 
of the NF-κB subunits and modulates the transcriptional 
responses.6–8 Interestingly suppression of canonical NF-κB 
activation by mutations or loss of NEMO increases NIK accu-
mulation with aberrant noncanonical NF-κB signaling.9 This 
suggests that the cross talk between the two pathways and a 
rate-limiting canonical NF-κB signaling perhaps determine 
the basal pool of NIK and the constitutive NF-κB activity.2,7,8
Induced activation of NF-κB p65:p50
The most abundant form of NF-κB activated by the canoni-
cal pathway is the heterodimer of p50 and p65.2 As stated 
above typically triggered by an NEMO-dependent activa-
tion of IKK, phosphorylation of IκB proteins followed by 
ubiquitination and degradation by proteasomes releases the 
NF-κB p65:p50 dimers from the inhibitory complex.4,9,10 
This exposes the arginine- and lysine-rich NLS of the p65 
and the p50 subunits for interaction with the importin α/β 
heterodimers and nuclear translocation11 (Figure 1). Mecha-
nistically, most often the importin α proteins initially bind 
the NLS and then recruit importin β to transport the cargo 
into the nucleus through the nuclear pore complexes (NPCs). 
However, importin β has been shown to directly bind the 
NLS of p65 and promote its nuclear translocation.11,12 Within 
the nucleus, the Ran-GTP protein binds and dissociates the 
importin-β from the complex with p65. The free p65 then 
binds specific nucleotide sequence of the target genes and 
mediates tightly controlled transcriptional programs that 
exhibit a wide degree of tissue- and context-specificity.13–16 
Sequence-specific DNA-binding of p65 is greatly stimulated 
by the interaction with various components of the basic tran-
scription machinery such as the TFIIB, TBP-associated fac-
tors and several coactivators including p300 and Tip60.15,17,18 
Export of p65 out of the nucleus is facilitated by the exportin 
proteins that bind the nuclear export sequence of p65 and the 
Figure 1 Model for basal and induced NF-κB p65 activity.
Notes: Basal NF-κB activity is potentially maintained by a balanced shuttling of the NF-κB p65:IκB complex between the cytoplasm and nucleus. In a steady-state condition, 
IκBα masks entirely the nuclear localization signal of p65 but not that of p50. This allows shuttling of the NF-κB:IκB complex by passive nuclear import to support basal 
activity and reciprocal export by the nuclear export signals in the terminal ankyrin repeat of IκBα. Stimulus induced phosphorylation of IKKβ followed by protein kinase-A-
mediated phosphorylation of IκBα and rapid release and import of p65:p50 dimers. Postinduction, the newly synthesized IκBα not only sequesters DNA bound p65 but also 
shuttles to the cytoplasm to quench the free p50:p65 dimers.
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Ran GTP. The complex then passes through the NPC into the 
cytoplasm, wherein hydrolysis of Ran GTP to Ran GDP by 
Ran GTPase-activating protein results in the dissociation of 
p65.7,8 Structural analyses of the NF-κB:IκB complex showed 
that the IκB proteins mask the NLS of p65 but not that of 
the p50 subunit.19–21 Hence, in physiologic conditions the 
importin α/β dimers can bind the NLS of p50 and facilitate 
the nuclear import of p50:p65 dimers. Exportin proteins 
bind the nuclear export sequence of IκBα in complex with 
the p65 in the nucleus and facilitate export of the complex 
out of the nucleus (Figure 1). Continuous shuttling of the 
NF-κB:importin:IκBα complex between the nucleus and 
cytoplasm maintains a low level of basal p65 activity.4,19,22
Mechanisms and modulations of the 
p65-mediated transactivation
Induced activation of p65 in response to a variety of stimuli 
is typically transient but sufficient to upregulate transactiva-
tion of target genes of diverse activities such as the cellular 
proliferation, inflammatory cytokines, chemokines, and 
mediators of apoptosis.1,23,24 It is tightly controlled by postin-
duction termination via negative feedback loops. Different 
importins including the importin α3, α4, α5, and β1 exhibit 
variable affinities for binding the p65 NLS and hence compete 
with or substitute for each other in facilitating its nuclear 
import.11,25 Furthermore, the expression levels of importin 
α and importin β have been shown to vary widely in differ-
ent cells and tissues.26 Hence, the combined effects of the 
expression levels of the importin proteins and the differential 
p65 affinities determine the extent of nuclear translocation of 
p65 and subsequent transactivation. Efficient and controlled 
transactivation of the target genes is facilitated by cross talk 
with other transcription factors with either synergistic (eg, 
AP-1) or antagonistic (eg, cEBP/β) effects.2,27 In addition, a 
variety of posttranslational modifications including degrada-
tion and regulatory ubiquitination, acetylation, methylation, 
and phosphorylation play key roles in the fine-tuning and 
specification of the NF-κB p65 activation outcomes. These 
modifications often occur in a hierarchical manner with 
phosphorylation or acetylation as typical starting points 
and degradative ubiquitination as characteristic irreversible 
endpoints.4,28
p65 phosphorylation
Inducible p65 phosphorylation can occur both in the cyto-
plasm and in the nucleus in response to a variety of stimuli.4,28 
Phosphorylation is mediated by protein kinases that transfer 
the γ-phosphate of adenosine triphosphate to the hydroxyl 
group of a serine (Ser), threonine (Thr), or tyrosine (Tyr) 
residue of the target protein.29 The NF-κΒ p65 possesses 
many Ser and Thr residues distributed in the RHD and the 
TAD. Phosphorylation of individual Ser/Thr/Tyr by multiple 
kinases generates a heterogeneous pool of modified NF-κΒ 
p65 that transactivates genes and mediates context-dependent 
functional responses.4,28
Ser-276 in p65 RHD is predominantly phosphorylated by 
protein kinase A (PKAc). In resting cells, the catalytic sub-
unit of PKAc is masked by the cytosolic IκΒ:p65 complex. 
Activation of the IKK complex releases the PKAc, which in 
turn phosphorylates Ser-276 inducing a structural change 
in p65 that facilitates interaction with the cofactors p300/
CBP (cAMP response element binding [CREB] protein) and 
enhances transcriptional activity.30 The mitogen and stress-
activated protein kinase-1 (MSK-1)/MSK-2 phosphorylates 
Ser-276 in the nucleus and enhances inflammatory gene 
expression.4,9,31 This MSK1/2-mediated phosphorylation 
depends on the nature of stimuli and may require additional 
kinases such as casein kinase 2 and ribosomal s6 kinase 
(RSK1).9,28
Phosphorylation of p65 at Thr 254 leads to a phosphory-
lated Thr–proline motif that is recognized by the peptidyl-pro-
lyl isomerase Pin1. Pin1-mediated prolyl isomerization of p65 
results in reduced IκBα binding, increased p65 stability, and 
nuclear accumulation mediating enhanced  transcription.4,32 
Mutation of Thr 254 dramatically reduced the half-life of p65 
protein and inhibited p65 transcriptional activity.32
Phosphorylation of Ser-468 in p65 T mediated by IKKε 
or glycogen synthase kinase 3β in unstimulated cells has 
been shown to negatively regulate basal NF-κB activity.33,34 
Phosphorylation of Thr-505 by checkpoint kinase 1 has been 
identified as a means of cross talk between DNA damage and 
the activation of NF-κB.4,35
Ser-536 in the p65-TAD is also phosphorylated by 
multiple kinases including IKK kinases, RSK1, and NF-κB 
activating kinase/TNFR-associated factor NF-κB activator 
(TANK)-binding kinase 1 (TBK1).36–38 While phosphoryla-
tion of Ser536 in the cytosolic p65 by IKK or RSK1 promotes 
its nuclear translocation,37 cyclin-dependent kinase-6 (CDK-
6) phosphorylates Ser-536 in the nucleus and facilitates p65 
binding to specific promoter sequences. Inhibition of CDK-6 
catalytic activity suppressed NF-κB p65-mediated inflam-
matory gene expressions.39,40 Interestingly Ser-536 has also 
been shown to be phosphorylated by TBK1 (TANK-binding 
kinase 1), a Ser-Thr kinase, belonging to the noncanonical 
IκB kinases, suggesting that the two NF-κB pathways are 
interrelated at multiple levels.41 Taken together, modulation 
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of the Ser-536 phosphorylation status is another mechanism 
for self-limited activation of NF-κB.
Acetylation
Lysine acetylation is a reversible event regulated by his-
tone acetyltransferases (HATs) and histone deacetylases 
(HDACs).42 Seven acetylation sites are identified in p65: 
Lys122, Lys123, Lys218, Lys221, Lys310, Lys314, and 
Lys315. The HATs p300 and p300/CBP-associated factor 
(PCAF) acetylate lysines 122 and 123 of p65. The p300 has 
also been described to acetylate lysines 310, 314, and 315.28,43 
Acetylation of specific lysine residue has been shown to regu-
late NF-κB p65 activation or deactivation. While acetylation 
on Lys122 and Lys123 decreases DNA binding, Lys221 and 
Lys218 acetylation enhances the DNA binding of NF-κB 
p65 by impairing its association with IκBα.44,45 Although 
acetylation at Lys310 is critical for full transcriptional activity 
of p65, it does not affect the DNA binding or assembly with 
IκΒα.43,46 Lys314 and Lys315 acetylation increases promoter 
selectivity without affecting the NF-κB p65 shuttling or the 
DNA binding.43,47 The acetylated Lys310 is specifically rec-
ognized by the two bromodomains of Brd4, which recruits 
activated CDK9 to phosphorylate RNA polymerase II for the 
transcription of a subset of NF-κB target genes.28,48
Tip60 (HIV Tat-interacting protein, 60 kDa), originally 
identified as a binding partner for the HIV-1 Tat protein, 
has been shown to function as a coactivator of NF-κB p65, 
enhance acetylation on Lys310, and upregulate p65 tran-
scriptional activity through a protein–protein interaction.49 
The Tip60 has been shown to bind DNA prior to p65 and 
potentially modulate other cofactor:p65 interactions. This 
suggests that the site-specific early association of Tip60 could 
represent another mechanism that regulates p65-mediated 
gene expression.
Methylation
The protein methyltransferases include two enzymes, the pro-
tein lysine methyltransferases and the protein arginine meth-
yltransferases (PRMTs). Both enzymes use small-molecule 
cofactor, S-adenosyl-l-methionine, as the universal methyl 
donor for the enzymatic methylation of lysine and arginine 
side chains.50,51 Methylations of both lysine and arginine on 
NF-κB p65 has been shown to regulate its transactivation 
potential.51–53
It has been suggested that the methylation of p65 in the 
nucleus potentially facilitates binding to specific promot-
ers when the local chromatin remodeling machinery is 
active.50 Set9, a histone methyltransferase, has been shown 
to  methylate p65 on Lys314 and Lys315 and negatively regu-
late the NF-κB function by inducing the ubiquitination and 
degradation of DNA-bound p65.54 In contrast, methylation 
of Lys37 by Set9 or that of Lys218 and Lys221 by nuclear 
receptor-binding SET domain-containing protein 1, a histone 
H3K36 methyltransferase, enhances the transcriptional activ-
ity by stabilizing binding of p65 to its enhancers.52,55 Apart 
from lysine residues, demethylation of Arg 30 by protein 
arginine methyltransferase 5 (PRMT5) has been shown to 
activate p65 suggesting that the methylation of both lysine 
and arginine residues regulate NF-κB-mediated transcrip-
tional activity.50,53 Molecular modeling suggests that methyl-
ated R30 can mediate Van der Waals contacts and increase 
the affinity of p65 for DNA and consequent transactivation 
of target gene expressions.53 Hence, differential methylation 
could represent another regulatory mechanism for differential 
activation of individual genes based on the cell type, stimulus, 
and other factors.50,51
In summary, the sequential post-translational modifica-
tions modulate the strength and duration of NF-κB activity, 
contribute to the target gene specificity, and thereby fine-tune 
the biologic responses.28,38,56 Indeed, it has been observed 
that the phosphorylation of Ser276 followed by acetylation 
of Lys310 of p65 facilitated recruitment of specific elonga-
tion factors Brd4 and P-TEFb to proinflammatory target 
genes promoting efficient mRNA processing.57 Furthermore, 
cross-talk mechanisms link post-translational modification-
mediated regulations. For example, phosphorylation at Ser-
276 and Ser-536 enhances the p300- and PCAF-mediated 
acetylation of Lys122, Lys123, and Lys310 and upregu-
lates transcriptional activation by p65.58 Thus, by virtue of 
modifying the interaction of p65 with select cofactors, the 
post-translational modifications at specific sites contribute 
to specific biologic responses.54,57
The varied and differential outcomes following individual 
site phosphorylation or acetylation have been attributed to 
the induced conformational changes in p65 that direct sub-
sequent cofactor interactions required for transcriptional 
activation.4,59 In this context it is of interest to note that 
the p65-TAD critical for its transcriptional ability hosts 
multiple phosphorylation sites and is largely unstructured.4 
The intrinsic disorder of the unstructured p65-TAD confers 
intramolecular flexibility that allows it to adopt an “induced 
fit” secondary structure stabilized by phosphorylation of 
specific residue in the context of an interacting cofactor.28,59 
Such intrinsically unstructured protein regions could serve 
as potential targets for rational drug design based on the 
transition from disordered to ordered conformation through 
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intermolecular interaction.60 Interestingly synthetic peptides 
derived from the p65-TAD have been shown to inhibit NF-kB 
p65-mediated cellular responses.61
Termination of activated p65
To avoid excessive transactivation and deleterious cel-
lular responses, the activated NF-κΒ p65 orchestrates a 
highly coordinated termination program that is rapid and 
self-limiting.
Role of IκBα
As stated above, NF-κB activity is predominantly controlled 
by association with IκBα. Following translocation, the 
nuclear p65 binds on the κB sequence in IκBα promoter and 
increases its transcription. The increased nuclear IκBα in turn 
removes the NF-κB p65 complex from the DNA terminating 
its transcriptional activity.19,22 As nuclear p65:DNA interaction 
exhibits fast dissociation kinetics, the newly synthesized IκBα 
may not only reverse the binding of p65 to DNA, but also 
capture p65 molecules released from DNA and transport them 
back to the cytoplasm.20,38 The iterative cycles of IκBα deg-
radation and replenishment by p65-mediated transactivation 
provide sustained supply of p65:p50 dimers to the nucleus at 
a basal level.3,19 In addition, strong oscillations of the negative 
feedback regulation between the activated p65 and IκBα are 
monitored by the IκBβ and IκBγ, the inhibitory proteins that 
undergo slow degradation, exhibit limited activation potential, 
and prevent abundance of activated p65 in the nucleus.2,62
Dephosphorylation of p65: It is another mechanism that 
facilitates termination of NF-κB signaling after stimulant 
removal or target gene expression and reestablish normal 
responsiveness. Dephosphorylation of Ser-536 by protein 
phosphatase 2A or by wild-type p53-induced phosphatase 
1 has been shown to reduce the interaction of p65 with p300 
and thereby inhibit gene expression.4,63,64 However, much like 
phosphorylation, dephosphorylation of p65 by phosphatases 
regulates the functions of NF-κB p65 in a context- and 
signal-dependent manner. For example, following cisplatin 
stimulation, phosphatase 4-mediated dephosphorylation 
of Thr-435 upregulated NF-κB p65 activation rather than 
suppression.65
Deacetylation of p65: Multiple HDACs deacetylate p65 
and regulate NF-κB functions depending on the specific 
acetylation site. While HDAC3-mediated deacetylation of 
p65 at Lys122, Lys123, Lys314, and Lys315 upregulated 
inflammatory gene expression, deacetylation at Lys218 and 
Lys221 promotes the binding of p65 with IκBα leading to 
the nuclear export and downregulation of NF-κB.43
Demethylation of p65: Similar to phosphorylation and acety-
lation, methylation is also a reversible event mediated by demeth-
ylases. Demethylation of methylated Lys-218 and Lys-221 by 
F-box and leucine-rich repeat protein 11, an H3K36 demethylase, 
has been shown to negatively regulate the transcriptional activity 
of NF-κB p65 and decrease cell proliferation.55,66
Ubiquitination and degradation: They have been sug-
gested as mechanisms that control the strength and duration 
of NF-κΒ activation.28,36 Nuclear p65 is degraded by the 
proteasome in a DNA-binding-dependent manner. Cop-
per metabolism domain protein, a physiologic inhibitor of 
NF-κΒ, binds to an E3 ligase SOCS1 (suppressor of cytokine 
signaling 1) and p65, stabilizing the p65:SOCS1 interac-
tion and thereby promote ubiquitination and degradation of 
p65.4,67 PDLIM2, a nuclear LIM domain containing ligase, 
mediates polyubiquitination and proteosomal degradation of 
nuclear p65 and contributes to the termination of p65-medi-
ated transactivation.10 Interestingly, point mutations in p65 
that inhibit DNA binding impaired degradation, suggesting 
that the sequence-specific interactions with DNA may be 
critical for transcriptional termination.
In conclusion, while cytoplasmic NF-κB p65 in complex 
with the IκBs are stable and do not undergo much turnover, 
the stability of nuclear p65 proteins is short-lived. Several 
interrelated not mutually exclusive mechanisms regulate the 
stability and termination of nuclear p65. In general, the postin-
duction repression of NF-κB p65 by newly synthesized IκBα 
can be considered upstream events that assist in maintaining 
the homeostasis between the cytoplasmic and nuclear p65. 
The nucleocytoplasmic shuttling mediated by the differential 
binding kinetics of p65 with different importin/exportin pro-
teins or modulations by dephosphorylation, demethylation, or 
deacetylation are intermediate mechanisms that contribute to 
effective p65 activation. For example, in conditions of continu-
ous stimulation, oscillations in Ser-536 phosphorylation have 
been shown to reflect oscillations in NF-κB cytosolic–nuclear 
translocation, suggesting potential dephosphorylation of Ser-
536 in the nucleus.37,68 Ubiquitination and proteosomal degrada-
tion of DNA-bound p65 constitute downstream events that play 
major roles in limiting the intensity and duration of NF-κB p65 
activity. In addition, the nature and extent of regulation by post-
translational modification can vary with different stimulators 
and even the same modifications can facilitate different effects.50
Therapeutic targeting of NF-κΒ p65 in 
inflammation
The literature is replete with a vast number of candidate 
therapeutics designed to target the NF-κB pathway. These 
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compounds belong to different chemical classes such as 
naturetics, peptidomimetics, small molecules, small interfer-
ing RNAs, and microbial products (Table 1).69–72 This review 
is restricted to therapeutic approaches that specifically target 
the interactions of the p65 subunit of NF-κB with a focus 
on inflammation, discussing representative compounds and 
illustrating emerging strategies to overcome the limitations 
of conventional NF-κB therapeutics (Figure 2).
Inhibitors of the NF-κB p65:IκΒ complex
As stated above, canonical activation of NF-κB p65 involves 
intracellular signaling networks that utilize adapter protein 
interactions, and phosphorylation and ubiquitination pro-
cesses that hinge on signal-induced proximity and appropri-
ate orientation of the multimeric subunits. Several chronic 
inflammatory pathologies are associated with dysregulated 
phosphorylation/activation of the NF-kB:IkB complex. 
Hence, preventing phosphorylation by using kinase inhibitors 
constitutes attractive therapeutic strategy. A vast number of 
kinase inhibitors target either the IKK complex or the adapter 
proteins in the NF-kB signal transduction pathway (please 
refer to excellent reviews3,71,73,74). The therapeutic potential 
of these kinase inhibitors has been predominantly evaluated 
in multiple cancers.3,74 While none of these have been shown 
to specifically target p65, a few affect the post-translational 
modifications in p65 by inhibiting the associated cofactors. 
Table 1 Strategies and agents developed and evaluated for selective targeting of NF-kB p65
Mechanisms of NF-κB p65 
inhibition
Targets Agents References
Inhibitors of the NF-κB p65:IκB 
complex
Kinase inhibitors Many, not specific for p65 71,73,75–77
Inhibitors that prevent p65 
nuclear translocation
Nucleocytoplasmic shuttling p65/
p50 NLS:importin interaction
·	 SN50 (NLS p50 peptide)
·	 Ant-pep 6
·	 BMS 274172 (D-amino acid NLS c-myc peptide)
·	 INI-43 (importin-β1 inhibitor)
78,79
80
81,82
83,84
p65 transactivation domain Competing peptide 61,93,94,100
93,94
100
GILZ mimetics
Smad4-binding domain peptide
Inhibiting activation of nuclear 
p65
DNA binding Decoy NF-κB nucleotides 102–106, 108
Cofactor inhibitors SeGRM, compound 10, PF-802
MG 149
113,114
118
Inhibitors of post-translational 
modifications
Acetylation
HAT inhibitor
HDAC inhibitors
Methylation/demethylation
Methyltransferase inhibitors
PCAF inhibitors, MG149
MS-275
KBH-A42
RGFP966
SIRT1 inhibitors
ePO15666
HLCL5
117,118
123,124
125
128
44,46,56
129
130
Notes: The table includes representative examples of agents evaluated for selective targeting of p65 in the context of chronic inflammation.
Abbreviations: HAT, histone acetyl transferase; HDAC, histone deacetylase; INI-43, inhibitor of nuclear import-43; NLS, nuclear localization signal; PCAF, p300/CBP-
associated factor; SeGRM, selective glucocorticoid receptor analog or modulator.
For example, p38 mitogen-activated protein kinase (MAPK) 
inhibitor has been shown to inhibit phosphorylation of the 
coactivator p300 and preclude acetylation on Lys310 of 
p65, thereby preventing DNA binding and transcriptional 
 activity.75 Second-generation p38 MAPK inhibitors are being 
evaluated in clinical trials for chronic inflammatory diseases 
such as COPD, Crohn’s disease, and Alzheimer’s disease.76,77
Inhibitors that prevent p65 nuclear translocation
a. NLS inhibitors: As stated above, nucleocytoplasmic shut-
tling of p65 is critical for transcriptional regulation of target 
genes. Binding of the p65 NLSs with the adapter proteins 
importins enables its translocation through the NPC.11,25 
Within the nucleus, importin is dissociated by GTPases and 
the activated p65 is released to initiate transcription.62 This 
suggests that inhibitors of the p65:importin adapter interac-
tions may be selective NF-κB inhibitors. It was proposed 
that rationally designed peptides derived from the NLS of 
the NF-κB subunits would suppress nuclear translocation of 
p50:p65 dimers by competitively inhibiting their interaction 
with importins. A linear peptide of the p50 NLS sequence 
(SN50) covalently synthesized with a cell-permeable com-
pound inhibited the nuclear import of NF-κΒ p65 in human 
monocytic cells and murine endothelial cells stimulated with 
the proinflammatory agonists such as lipopolysaccharide 
(LPS) or the cytokine TNF-α.78,79 Interestingly a short peptide 
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mimic (RLRWR) of the DNA binding motif of p50 designated 
as anti-inflammatory peptide-6 exhibited cell-penetrating 
ability, interacted directly with the p65 thereby inhibiting 
DNA binding and transactivation of inflammatory media-
tors.80 A cell-permeable peptide made up of NLS of c-myc 
has also been shown to inhibit nuclear translocation of p65 
and suppress T-cell responses in models of inflammation.81,82
b. Many inhibitors that directly target select importin-α, 
improtin-β, or exportin proteins have been developed to 
inhibit nuclear translocation of p65 and subsequent cellu-
lar responses. Examples of this class of inhibitors include 
small molecules such as inhibitor of nuclear import-43 and 
selinexor, a selective inhibitor of nuclear export compound 
that inhibits the exportin XPO1.83,84 The efficacy of these 
agents has been largely investigated in tumor models and is 
yet to be evaluated in inflammatory pathologies.
c. Blocking p65 TAD: This includes strategies that inhibit 
p65 independent of other rel proteins.
i. Competing p65 peptide: The p65 nuclear translocation 
and consequent transactivation of target genes is facilitated by 
interactions of p65-TAD with other transcription factors and 
cofactors. A conceptually simple strategy for development 
of inhibitors of interprotein interactions is to take advan-
tage of the evolutionary selection of residues for individual 
protein:protein interaction and design interface peptides 
derived from the primary sequence of one of the binding 
partners.85,86 As stated above, phosphorylation on Ser276, 
Ser529, Ser536, and Ser471 induces conformational changes 
in p65 and facilitates its binding with other transcriptional 
cofactors such as p300 and PCAF.59 Synthetic peptides 
encompassing these phosphorylation sites in p65 fused with 
a protein transduction domain have been shown to suppress 
Figure 2 Schematic representation of NF-κB p65 activation and potential inhibitors along the signaling pathway.
Notes: The inset shows phosphorylation and acetylation sites of p65 as sites of kinase inhibitors and HDACs. Representative inhibitory strategies along the pathway are 
shown. 
Abbreviations: NBD, NeMO binding peptide; GC, glucocorticoid; GILZ, glucocorticoid-induced leucine zipper; GR, glucocorticoid receptor; HDAC, histone deacytelases; 
NLS, nuclear localization signal; ODN, oligodeoxynucleotide; PCAF, p300/CBP-associated factor; TAD, transactivation domain.
Journal of Inflammation Research 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
414
Giridharan and Srinivasan
NF-κΒ activation induced by a variety of stimuli such as LPS, 
interleukin-1, okadaic acid, phorbol 12-myristate 13-acetate, 
and cigarette smoke condensate inflammatory stimuli.61 
ii. Glucocorticoids-mediated cytoplasmic sequestration 
of p65: The classical model for the therapeutic potential 
of glucocorticoids suggests that the direct binding of the 
glucocorticoid receptor on specific glucocorticoid receptor 
elements (GREs) in the promoter region upregulates transac-
tivation of anti-inflammatory genes.87,88 With six GRE in its 
promoter, glucocorticoid-induced leucine zipper is strongly 
upregulated by glucocorticoids.89 GILZ has been shown to 
physically bind the p65 TAD via its proline-rich region and 
inhibit NF-κΒ signaling.90,91 In protein interfaces, proline-
rich regions that adopt extended polyproline type II helical 
conformation constitute excellent drug templates with the 
specificity of the interaction determined by the residues adja-
cent to the interacting moieties in each partner.60,92 Synthetic 
peptide mimics of the p65 binding motif of GILZ suppressed 
nuclear translocation of p65, inflammation, and apoptosis.93,94
iii. The expanding network of NF-κB interactors has 
increased the potential for identifying newer targets for spe-
cific inhibition. Among the proteins that bind p65, a subset 
directly binds the TAD such as the p300,95,96 silencing media-
tor of retinoic acid and thyroid hormone receptors97 and the 
Smad proteins. Smads are a family of structurally similar 
proteins belonging to the TGF-β superfamily involved in 
regulating cell development and growth. In humans, eight 
Smads are known and are classified into three subtypes: five 
receptor-regulated Smads (R-Smads), one common partner 
Smad (co-Smad), and two inhibitory Smads (I-Smad). While 
the R-Smads mediate signaling from the TGF-β receptor and 
I-Smads suppress R-Smads, the co-Smad recruits coregula-
tors to the transcriptional factors and modules gene expres-
sions. Structurally, the Smad proteins have two conserved 
globular domains called the mad homology (MH) 1 and MH2 
domains.98 Recently, using co-immunoprecipitation assays, 
it has been reported that the TA2 domain of p65 physically 
interacted with the MH1 domain of Smad4.99 A peptide 
derived from the amino-terminal region of TA2 that associ-
ates with the MH1 domain of Smad4 covalently synthesized 
with a cell-permeable peptide prevented NF-κB signaling-
mediated inhibition of osteoblast differentiation by blocking 
the association of p65 with Smad4 and allowing increased 
bone morphogenetic protein-2 signaling.100
Inhibitors of nuclear p65
i. Decoy oligodeoxynucleotides (decoy ODNs): They consti-
tute a type of gene therapy and are made up of  double-stranded 
DNA fragments of the same sequence as the binding site of 
the transcription factor on DNA.101 Decoy ODNs possessing 
κB consensus sequence bind NF-κB p65, prevent it from 
interacting with the cis-element of specific target gene, and 
thereby inhibit initiation of the transcription process.102 Trans-
fection of NF-κΒ decoy ODNs to the arteries by hemaggluti-
nating virus of Japan liposomes prevented ischemia-induced 
myocardial infarction by suppressing expression of cytokines 
and adhesion molecules.103 Similar observation of protection 
against inflammation following decoy NF-κΒ ODNs has 
been reported in models of arthritis, colitis, cystic fibrosis, 
and atopic dermatitis.104–106 The relative ease of design and 
construction is a significant advantage of decoy ODNs as 
therapeutic agents. However, limited cellular uptake due to 
the negative charge and large size as well as severe toxicities 
due to lack of cellular restrictions is a potential drawback. 
Recently, several strategies have been developed for success-
ful and targeted delivery of decoy ODNs such as the use of 
nanoparticles and ultrasound-targeted microbubbles.101,107 
NF-κΒ decoy ODNs in such formulation are currently in 
clinical trials for atopic dermatitis and discogenic low back 
pain, and they appear to be well tolerated, nontoxic, and 
potentially efficacious108 (www.anges.co.jp).
ii. Selective glucocorticoid receptor agonists (SEGRA): 
Cross talk between the NF-κB and the GR signaling occurs 
at multiple levels such as the physical interaction between 
the DNA binding domain of GR and the nuclear p65, direct 
interference of GR with p65 and associated basal transcrip-
tion machinery, and competitive binding of co-activators such 
as PKAc or CBP.87,109,110 Many SEGRA or dissociated agonists 
of glucocorticoid receptor based on steroidal scaffold or non-
steroidal modulators of the glucocorticoid receptor (SEGRM) 
developed to selectively facilitate that transrepressive actions 
are enhanced have been shown to inhibit NF-κB-mediated 
inflammatory responses.111–113 In this context it has been 
reported that coactivation of GR and p65 results in their 
association at binding sites that cluster with p65 target genes 
suggesting competition between GR and p65 for binding 
specific response elements.87 Interestingly, SEGRM of the 
family of diabenzoxepane or dibenzosuperane (compound 
10, PF-802, Fosdagocorat) that bind GR at sites other than 
the ligand (glucocorticoid)-binding domain induce confor-
mational changes precluding GR binding the GRE.113,114 
Together with the enhanced potential for the nuclear GR to 
compete for the co-activators, the anti-inflammatory effects 
of such SEGRM could be attributed to specific inhibition of 
NF-κB p65.113,115,116 Elucidation of these mechanisms would 
also assist in adopting the information from the GR:p65 
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interactome in developing agents that provide beneficial 
(predominantly transrepressive) effects of glucocorticoids 
while avoiding the serious adverse responses.
Inhibitors of post-translational modifications
The dynamic nature of the PTMs in regulating gene expres-
sion patterns makes this system particularly amenable for 
epigenetic drug discovery. Considerable evidence suggests 
that the NF-κB p65 PTMs are deregulated in conditions of 
chronic inflammation and autoimmune diseases.28,58 Target-
ing the p65 PTM sites or the protein:protein interactions 
represents powerful approaches for amelioration of these 
conditions. Although all PTMs are important components 
of the epigenome, acetylation network consists of a large 
number of druggable targets.
i. HAT inhibitors: As stated above, HATs are epigenetic 
enzymes that add acetyl groups onto lysine residues of 
proteins including NF-κB p65. The following include few 
examples of HAT inhibitors that selectively target lysine 
residues on p65.
PCAF inhibitors: The PCAF inhibitors specifically acety-
late only Lys-122 of p65 and blocking of this acetylation 
could diminish the nuclear retention and transcriptional activ-
ity of p65.42,45 Specific inhibitors of PCAF developed using 
structure-based design and molecular docking have been 
shown to inhibit p65-induced transactivation of inflamma-
tory mediators in stimulated macrophages and glial cells.117
Tip60, a member of the MYST family of co-activators, 
has been shown to activate p65-mediated transcription by 
maintaining the Lys310 in the acetylated state.49 Analogs of 
the naturally occurring anacardic acid (6-pentadecylsalicylic 
acid/MG 149) that inhibit Tip60 have been shown to reduce 
proinflammatory gene expression in murine precision cut 
lung slices (PCLS).42,118
ii. HDAC inhibitors: Several studies have reported the 
potential of small-molecule HDAC inhibitors to regulate p65 
acetylation.43,119 The functional efficacy of pan-HDAC inhibi-
tors in multiple cancers has been reviewed extensively.120–122 
The following are few examples of HADC inhibitors that 
have been shown to modulate inflammation.
NF-κB p65 acetylation on Lys 310 by a HDAC1–3 
inhibitor, MS-275, has been shown to exert mixed effects 
depending on the cell type and the nature of the stimuli. In 
LPS-stimulated macrophages and murine PCLS, treatment 
with MS-275 upregulated both anti-inflammatory and pro-
inflammatory cytokines.123 Similarly, in poly(I-C)-induced 
dendritic cells, MS-275 reduced the release of both the 
proinflammatory TNF-α, IL-6, and IL-12 cytokines and 
the anti-inflammatory IL-10.124 In contrast, in a model of 
cigarette smoke-exposed lung inflammation that mimics 
the human COPD, MS-275 treatment robustly attenuated 
the expression of inflammatory chemokines and decreased 
neutrophil influx in the lungs.123 Another HDAC 1–2 inhibitor, 
KBH-A42, reduced LPS-induced endotoxemia.125 With both 
NLS and nuclear export sequence, HDAC-3 exerts proinflam-
matory effects.126 Silencing HDAC-3 reduced vascular cell 
adhesion molecule 1, monocyte recruitment, proinflamma-
tory transcriptional activity, and disease progression in an 
allergic skin inflammation model.126 In human macrophages, 
HDAC3 siRNA inhibited cytokine response to LPS.127 In 
contrast to the multiple HDAC inhibitor MS 275, treatment 
with RGFP966, a selective and potent inhibitor of HDAC-3, 
upregulated IL-10 and exhibited anti-inflammatory effects 
in response to LPS/IFNγ in macrophages and in mouse 
PCLS.128 Deacetylation of Lys-310 by the HDAC SIRT1 
has been shown to inhibit p65-mediated transactivation of 
cytokines and apoptosis mediators.46 Inhibiting the activity 
of SIRT1 markedly increased the acetylation of Lys-310 and 
the transcriptional activity of NF-κB.44,56
The arginine methyltransferase, PRMT5, that demethyl-
ates R30 of p65 plays a key role in regulating endothelial 
cell inflammation, proliferation, and differentiation.66,123 
Increased expression of PRMT5 that correlates with the 
enhanced inflammatory cytokines has been observed in 
the synovial tissues in rheumatoid arthritis. Inhibition of 
PRMT5 with a specific inhibitor EP015666, has been shown 
to decrease phosphorylation of IKK and IKBα, reduce trans-
activation of inflammatory cytokines, and suppress fibroblast 
migration potentially ameliorating disease progression in 
arthritis.129 Another PRMT5 inhibitor, HLCL65, has been 
shown to selectively inhibit pathogenic T cells in a mouse 
model of multiple sclerosis.130 Taken together these observa-
tions suggest that the manipulation of specific acetylation 
sites in p65 can lead to resultant proinflammatory or anti-
inflammatory effects.
Conclusion
Overwhelming evidence supports a critical role of increased 
NF-κΒ p65-mediated transactivation in the pathogenesis 
of multiple chronic inflammatory diseases. The beneficial 
effects of many natural compounds such as the curcumin 
and that of the synthetic inhibitors of upstream signaling 
molecules such as the cytokine and cytokine receptor antago-
nists in chronic inflammatory diseases have been attributed 
to reduced NF-κΒ p65 signaling.3,69–71,101 Hence, targeting 
p65 activation directly for better clinical efficacy has been a 
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long-sought-after goal. As discussed earlier, several strate-
gies to block p65 at each level along the path of signaling 
have been assessed and novel strategies are being developed. 
However, a critical hurdle is selective targeting of activated 
p65 without the off-target effects. In this context, steric 
blockade of p65-TAD using GILZ mimetics or mimics of 
the p65:Smad4 interface appears to be a promising strategy 
to selectively inhibit activated p65.91,100,131 Targeted intracel-
lular delivery in a context- and tissue-specific manner is 
another drawback that impedes development of effective p65 
inhibitors. It is anticipated that advances in nanotechnology-
based delivery systems will assist in not only improving the 
pharmacokinetic profile but also facilitate contextual deliv-
ery of drugs and drug-like agents. Recently, a nanocarrier 
delivery system consisting of a functional cell-penetrating 
stearoyl-oligopeptide was used for effective delivery of two 
RNAi agents that silenced p65 mRNA in macrophages and 
exerted therapeutic effects in a model of atopic dermatitis.132 
The properties of biocompatibility and stability in body fluids 
and lack of immunogenicity make nanocarriers as ideal por-
tals for drug delivery. In future, development of engineered 
nanocarriers will not only facilitate targeted delivery but also 
accommodate conformational changes needed for efficacious 
intracellular p65 inhibitors.1,133
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